Qol Holdings (3034) Q3 2025 earnings summary

Executive summary

• Achieved record high consolidated sales and operating profit for the nine months ended December 31, 2024, driven by segment expansion and the consolidation of DAIICHI SANKYO ESPHA CO., LTD.

• DAIICHI SANKYO ESPHA became a consolidated subsidiary, significantly impacting sales and profit structure.

• Reporting segments were reorganized to reflect the expansion of the Pharmaceutical Manufacturing Business.

• EBITDA surged 76.6% to ¥16,963 million year-over-year.

• Comprehensive income rose 53.1% to ¥5,788 million year-over-year.

Financial highlights

• Net sales rose 47.3% year-over-year to ¥198,207 million for the nine months ended December 31, 2024.

• Operating profit increased 92.6% year-over-year to ¥11,034 million; ordinary profit grew 74.2% to ¥11,361 million.

• Profit attributable to owners of parent decreased 6.6% year-over-year to ¥3,524 million.

• Gross profit margin improved to 15.3% from 12.6% year-over-year.

• Gross profit increased to ¥30,404 million from ¥16,968 million year-over-year.

Outlook and guidance

• FY2024 full-year forecast: net sales ¥270,000 million, operating profit ¥15,000 million, ordinary profit ¥15,200 million, profit attributable to owners of parent ¥5,000 million.

• Progress rates for net sales, operating profit, and ordinary profit are all above 70% of full-year targets after three quarters.

• Basic earnings per share forecasted at ¥133.68 for the full year.